Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: A randomized clinical trial in 509 patients

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1666-1673

  Bal, C S ^a   Kumar, Ajay ^a   Pant, G S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG ACTIVITY; DRUG UPTAKE; FEMALE; FOLLICULAR CARCINOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIODINATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SUBTOTAL THYROIDECTOMY; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 1942537080     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031152     Document Type: Article

References (46)

1. Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri L 1998 Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 133:89-93
2. Vassilopoulou-Sellin R, Klein MJ, Smith TH, Samaan NA, Frankenthaler RA, Goepfert H, Cangir A, Haynie TP 1993 Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 71:1348-1352
3. 131I uptake postthyroidectomy for thyroid cancer. J Clin Endocrinol Metab 50:734-739
4. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121-1127
5. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL 1998 Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab 82:4116-4122
6. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol and Metab 71:414-424
7. Mazzaferri EL 1991 Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc 66:105-111
8. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
9. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720
10. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB 1998 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 14:1063-1075
11. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP, Parmentier C 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 55:794-804
12. Wong, JB, Kalpan MM, Meyer KB, Paukar SG 1990 Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am 19:741-760
13. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306
14. Freitas JE, Gross MD, Ripley S, Shapiro B 1985 Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 15:106-131
15. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 96:1447-1463
16. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129:622-627
17. Hay ID, McConahey WM, Goellner JR 2002 Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241-260
18. Ramanna L, Waxman A, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD 1985 Evaluation of low-dose ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 10:791-795
19. Beierwaltes WB 1987 Radioiodine therapy of thyroid disease. Int J Rad Appl Instrum B 14:177-181
20. 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 52:763-773
21. McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD 1976 Low dose radioiodine thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 61:52-58
22. Siddiqui AR, Edmondson J, Wellman HN, Hamaker RC, Lingeman RE, Park HM, Johnston CC 1981 Feasibility of low doses of 131-I for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6:158-161
23. DeGroot LJ, Reilly M 1982 Comparison of 30-and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 96:51-53
24. Ramacciotti C, Pretorius HT, Line BR, Goldman JM, Robbins J 1982 Ablation of nonmalignant thyroid remnants with low does of radioactive iodine: concise communication. J Nucl Med 23:483-489
25. Becker DV, Hurley JR, Motazedi A, Cahill FT 1982 Ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer can be achieved with less whole-body radiation. J Nucl Med 23:43
26. Creutzig H 1987 High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 12:500-502
27. Johansen K, Woodhouse NJ, Odugbesan O 1991 Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 32:252-254
28. Leung SF, Law MW, Ho SK 1992 Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases. Br J Radiol 65:905-909
29. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 77:2574-2580
30. Utiger RD 1997 Follow-up of patients with thyroid carcinoma. N Engl J Med 337:928-930
31. Heidinger LE, Sobin LH 1974 International histological classification of rumors. Geneva: World Health Organization; 17-26
32. Thomas SR, Maxon HR, Kereiakes JG, Saenger EL 1977 Quantitative external counting techniques enabling improved diagnostic and therapeutic decisions in patients with well-differentiated thyroid cancer. Radiology 122:731-737
33. Snyder J, Gorman C, Scanion P 1983 Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 24:659-665
34. Maxon HR, Thomas SR, Samaratunga RC 1997 Dosimetric considerations in the radioiodine treatment of macrometastasis and micrometastasis from differentiated thyroid cancer. Thyroid 7:183-187
35. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F 1984 Pulmonary metastases in differentiated thyroid carcinoma: study of 58 cases with implications for the primary tumor treatment. Cancer 53:982-992
36. Tsang TW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB 1998 The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82:375-388
37. Mazzaferri EL 1997 Thyroid remnant 131-I ablation for papillary and follicular thyroid carcinoma. Thyroid 7:265-271
38. Benua RS, Cicle NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR Am J Roentgenol 87:171-182
39. Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S 1984 An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 25:1287-1293
40. Grigsby PW, Siegel BA, Baker S, Eichling JO 2000 Radiation exposure from outpatient radioactive iodine (131-I) therapy for thyroid carcinoma. J Am Med Assoc 283:2272-2274
41. 131I for remnant ablation in patients with differentiated thyroid carcinoma (author reply). Cancer 79:190-191
42. Maxon HR, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD 1992 Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33:1132-1136
43. Samuel AM, Rajshekarrao B 1994 Radioiodine therapy for well-differentiated thyroid cancer: a quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med 35:1944-1950
44. Lin JD, Kao PF, Chao TC 1998 The effect of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol 71:307-313
45. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068
46. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness of postsurgical remnant ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115